NEW YORK--(BUSINESS WIRE)--May 31, 2006--Bioenvision, Inc. (Nasdaq:BIVN - News) today announced the European Commission has granted marketing authorization for Evoltra(TM) (clofarabine) for the treatment of acute lymphoblastic leukemia (ALL) in pediatric patients who have relapsed or are refractory to at least two prior regimens and where there is no other treatment option anticipated to result in a durable response. The licensed indication includes patients who were less than 21 years at the time of initial diagnosis of their leukemia.
